Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Rezolute, Inc.

Chiesi Global Rare Diseases is a biopharmaceutical company focused on providing innovative therapies for individuals affected by rare diseases.

Chiesi Global Rare Diseases

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

John Klock

Emil D. Kakkis

Ultragenyx Pharmaceutical Inc.

Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing therapies for rare diseases, specifically hyperinsulinism.

Metric
Company Name	Rezolute, Inc.	Chiesi Global Rare Diseases	Sarepta Therapeutics, Inc.	Ultragenyx Pharmaceutical Inc.
Symbol	RZLT		SRPT	RARE
MSH ID	COM:REZOLUTEBIO	COM:CHIESIRAREDISEASES	COM:SAREPTA	COM:ULTRAGENYX
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Pharmaceuticals	Biotechnology	Biotechnology
Country	US	US	US	US
Stage			Post-IPO Equity
Employee Count	41		1.31K	1.28K
Website	rezolutebio.com	chiesirarediseases.com	sarepta.com	ultragenyx.com
LinkedIn				ultragenyx-pharmaceutical-inc-
Founders

Metric
Market Cap	220.96M	14.11B	3.85B
Enterprise Value
Monthly Web Traffic		12.98K	21.29K
Web Traffic Growth		-0.26	0.36
Valuation
Raised Capital		5.96M	350M

Metric
Revenue	1.24B	434.25M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.09B	389.04M
EBITDA	-267.82M	-516.85M
Operating Income	-267.82M	-569.21M
Net Income	-535.98M	-606.64M
EPS	-5.80	-8.25
Diluted EPS	-5.80	-8.25
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.88	0.90
Operating Profit Margin	0.03	-1.14
EBITDA Margin	-0.22	-1.19
Net Profit Margin	0.03	-1.22
Return on Equity	0.05	-2.66
Return on Assets	0.01	-0.36
Return on Capital Employed	0.01	-0.41

COM:REZOLUTEBIO

Rezolute, Inc.

Last Close

4.86

22/11 21:00

Market Cap

220.96M

Beta: -

Volume Today

372.53K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-16.13	-5.06
P/B Ratio	14.58	101.28
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.03	11.42
EV Multiple	207.35	-4.38

Metric
Days Sales Outstanding	117.02	70.53
Days Payables Outstanding	234.37	316.43
Days Inventory Outstanding	958.33	274.25
Operating Cycle	1.05K	335.94
Cash Conversion Cycle	841.56	51.68
Asset Turnover	0.44	0.34

Metric
Operating Cash Flow	-500.99M	-474.81M
Free Cash Flow	-588.34M	-521.57M
Cash Flow to Debt	-0.32	-0.52
Operating Cash Flow/Sales	-0.26	-0.98
Free Cash Flow Yield	-0.05	-0.11

Metric
Cash & Equivalents	428.43M	213.58M
Accounts Receivable	-185.70M	-22.78M
Inventory	322.86M	33.97M
Goodwill		44.41M
Debt to Capitalization	0.59	0.87
Debt to Assets	0.54	0.01
Current Ratio	5.44	2.06
Quick Ratio	3.44	3.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.17	0.32
R&D to Revenue	0.81	1.61
SG&A to Revenue	0.43